Why the study?
It remained unclear whether indobufen-based DAPT preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease.
Does indobufen plus clopidogrel reduce bleeding events and preserve ischemic protection compared to aspirin plus clopidogrel in patients with multivessel coronary disease undergoing drug-eluting stent implantation?
Does indobufen plus clopidogrel reduce bleeding events and preserve ischemic protection compared to aspirin plus clopidogrel in patients with multivessel coronary disease undergoing drug-eluting stent implantation?
Indobufen-based DAPT is an effective and safer alternative to aspirin-based DAPT for reducing bleeding risk without compromising ischemic protection in patients with multivessel coronary disease undergoing PCI.
Answers are grounded in this paper and cite their sources.
Indobufen-based DAPT may reduce bleeding without excess ischemia post-PCI in MVD; extends RCT evidence for aspirin alternatives in high-bleeding-risk subsets.
BACKGROUND: It remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD. METHODS: Patients in the OPTION trial were stratified based on the presence of MVD. We compared the ischemic and bleeding risks of indobufen-based DAPT (indobufen 100mg twice a day plus clopidogrel 75 mg/d for 12 months) vs conventional DAPT (aspirin 100 mg/d plus clopidogrel 75 mg/d for 12 months) in patients with and without MVD, using landmarks at 6 months and 1-year post-percutaneous coronary intervention (PCI). RESULTS: Patients with MVD tended to be older and contained a higher prevalence of high-risk features. Compared with patients without MVD, those with MVD were at higher risk for net adverse clinical events and ischemic events. The risk of ischemic events between indobufen-based DAPT vs conventional DAPT was similar either in patients with MVD or without MVD during the first and second 6 months. During the first 6 months, indobufen-based DAPT decreased the risk of bleeding events consistently in patients with and without MVD. Of note, during the second 6 months, indobufen-based DAPT continually decreased the risk of bleeding events in patients with MVD but not in those without MVD. CONCLUSIONS: In patients with MVD, indobufen plus clopidogrel DAPT compared to aspirin plus clopidogrel DAPT could reduce the risk of bleeding events while preserving ischemic protection during both the first and second 6 months post-PCI. Indobufen presents an effective option for patients with MVD, especially those at high ischemic risk requiring DAPT beyond 6 months post-PCI. TRIAL REGISTRATION: The trial was registered at www.chictr.org. A Randomized Controlled Trial of Indobufen vs Aspirin after Coronary Drug-eluting Stent Implantation: the OPTION Trial (ChiCTR-IIR-17013505).
No takes yet. Share an insight, caveat, or question.
Xu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: